Private Equity firm Astorg launches global fertility company Nexpring Health after series of acquisitions
Pan-European private equity firm Astorg has announced the launch of Nexpring Health, a global MedTech company that provides tools and solutions for Assisted Reproductive Technology (ART).
The company has been formed through the acquisitions of a number existing businesses including Hamilton Thorne, Cook Medical’s Reproductive Health business, and the soon-to-be-completed acquisition of FUJIFILM Irvine Scientific’s Medical Media Business.
While private equity firms typically invest in existing businesses rather than creating their own, Astorg’s move to bring these businesses together and launch Nexpring Health is part of a trend where financial firms consolidate companies within a specific sector to build a dominant market player. This allows them to streamline operations, increase market share, and potentially boost profitability before exiting the investment through a sale or public offering.
Astorg aims to establish Nexpring Health as a leading provider of ART solutions, offering embryologists and fertility clinics a broad portfolio of tools to enhance reproductive medicine.
Wil Boren, Chief Executive Officer of Nexpring Health, emphasised the company’s focus on supporting fertility professionals:
“We firmly believe that the greatest impact on patient outcomes comes from empowering the professionals at the heart of fertility clinics—embryologists and clinicians. Our approach is deeply collaborative, working closely with these experts to understand their daily challenges and develop solutions that enhance their capabilities.”
Astorg, which has invested heavily in the healthcare sector, sees Nexpring Health as a long-term strategic play. Judith Charpentier, co-head of Astorg’s flagship fund and head of healthcare, highlighted the firm’s commitment:
“Nexpring Health is the result of a bold, creative investment strategy and a strong shared vision with Wil—built on Astorg’s deep expertise in MedTech and long-term partnership mindset.”
Astorg, which manages over €23 billion in assets, has built a reputation for investing in niche healthcare and MedTech firms. Its portfolio includes companies such as CordenPharma, OPEN Health, and Avania. Nexpring Health is its latest move in a sector experiencing growing demand as fertility treatments become increasingly sought after worldwide.
The new entity could play a key role in shaping the future of ART, providing fertility specialists with tools to enhance patient outcomes while navigating the complexities of reproductive medicine.